Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease

Acta Ophthalmologica

Volumn 93, Issue 6, 2015, Pages e475-e480

  Urzua, Cristhian A ^a,b,c   Velasquez, Victor ^a,b   Sabat, Pablo ^a,b   Berger, Osvaldo ^d   Ramirez, Sebastian ^b   Goecke, Annelise ^c,e   Vásquez, Darío H ^b   Gatica, Hector ^c,e   Guerrero, Julia ^c  

^a HOSPITAL DEL SALVADOR   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c UNIVERSITY OF CHILE   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^e HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

Author keywords

complications; first line treatment; functional outcomes; glucocorticoids; immunomodulatory treatment; prognostic factors; Vogt Koyanagi Harada disease

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOMODULATING AGENT; METHOTREXATE; PREDNISONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; ARTICLE; BONE MARROW SUPPRESSION; CHILE; CHRONIC DISEASE; COHORT ANALYSIS; CUSHING SYNDROME; DEPIGMENTATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; FUNDUS DEPIGMENTATION; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TINNITUS; TREATMENT DURATION; TREND STUDY; VISUAL ACUITY; VISUAL IMPAIRMENT; VOGT KOYANAGI SYNDROME; COMBINATION DRUG THERAPY; IMMUNOMODULATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; UVEOMENINGOENCEPHALITIC SYNDROME; YOUNG ADULT;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; UVEOMENINGOENCEPHALITIC SYNDROME; VISUAL ACUITY; YOUNG ADULT;

EID: 84947040065     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12648     Document Type: Article

References (26)

1. Abu El-Asrar AM, Al Tamimi M, Hemachandran S, et al., (2013): Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91: e486-e493.
2. Baker KB, Spurrier NJ, Watkins AS, et al., (2006): Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol 90: 1481-1485.
3. Bordaberry MF, (2010): Vogt-Koyanagi-Harada disease: diagnosis and treatments update. Curr Opin Ophthalmol 21: 430-435.
4. Byon IS, Kim JH, Lee JE, &, Oum BS, (2011): Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease. Clin Ophthalmol 5: 1589-1591.
5. Cuchacovich M, Solanes F, Diaz G, et al., (2010): Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 18: 200-207.
6. Errera MH, Fardeau C, Cohen D, et al., (2011): Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt-Koyanagi-Harada disease. Acta Ophthalmol 89: e357-e366.
7. Gangaputra S, Newcomb CW, Liesegang TL, et al., (2009): Methotrexate for ocular inflammatory diseases. Ophthalmology 116: 2188-2198.
8. Grimes DA, &, Schulz KF, (2002): Cohort studies: marching towards outcomes. Lancet 359: 341-345.
9. Jabs DA, Rosenbaum JT, Foster CS, et al., (2000): Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130: 492-513.
10. Jabs DA, Nussenblatt RB, Rosenbaum JT, & Standardization of Uveitis Nomenclature (SUN) Working Group (2005): Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140: 509-516.
11. Kacmaz RO, Kempen JH, Newcomb C, et al., (2010): Cyclosporine for ocular inflammatory diseases. Ophthalmology 117: 576-584.
12. Kempen JH, Daniel E, Gangaputra S, et al., (2008): Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15: 47-55.
13. Kim SJ, &, Yu HG, (2007): The use of low-dose azathioprine in patients with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 15: 381-387.
14. Kruh J, &, Foster CS, (2012): Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol 51: 29-46.
15. Lai TY, Chan RP, Chan CK, &, Lam DS, (2009): Effects of the duration of initial oral corticosteroid treatment on the recurrence of inflammation in Vogt-Koyanagi-Harada disease. Eye (Lond) 23: 543-548.
16. Moorthy RS, Hinomata H, &, Rao NA, (1995): Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 39: 265-292.
17. Nazari H, &, Rao NA, (2012): Resolution of subretinal fluid with systemic corticosteroid treatment in acute Vogt-Koyanagi-Harada disease. Br J Ophthalmol 96: 1410-1414.
18. Okada AA, (2005): Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13: 335-351.
19. Paredes I, Ahmed M, &, Foster CS, (2006): Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 14: 87-90.
20. Pasadhika S, Kempen JH, Newcomb CW, et al., (2009): Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148: 500-509.
21. Rajendram R, Evans M, &, Rao NA, (2005): Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin 45: 115-134.
22. Rao NA, Sukavatcharin S, &, Tsai JH, (2007): Vogt-Koyanagi-Harada disease diagnostic criteria. Int Ophthalmol 27: 195-199.
23. Read RW, Holland GN, Rao NA, et al., (2001): Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131: 647-652.
24. Read RW, Yu F, Accorinti M, et al., (2006): Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 142: 119-124.
25. da Silva FT, Damico FM, Marin ML, et al., (2009): Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: considerations on the different disease categories. Am J Ophthalmol 147: 339-345.
26. Sukavatcharin S, Tsai JH, &, Rao NA, (2007): Vogt-Koyanagi-Harada disease in Hispanic patients. Int Ophthalmol 27: 143-148.